Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

America's biopharmaceutical researchers work on many new approaches to fight cancer

America's biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

Distinctive protein pathways in certain leukemia patients

Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.

1 Jun 2012

Kindstar, Insight Genetics collaborate to improve cancer care in China

Molecular diagnostics company Insight Genetics and Kindstar Globalgene Technology, Inc., China's leading diagnostics company, today announced that the companies are partnering to enhance cancer care in the People's Republic of China and surrounding regions.

1 Jun 2012

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

Ventana Medical Systems, Inc., a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein.

1 Jun 2012

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.

31 May 2012

Study examines how SMIP-016 drug kills CLL cells

A new study has identified a life-and-death signaling role for a molecule on the surface of the immune cells involved in the most common form of chronic leukemia. The finding could lead to more effective therapy for chronic lymphocytic leukemia (CLL), an as yet incurable cancer that occurs in more than 16,000 Americans annually.

31 May 2012

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

Cell Therapeutics, Inc. today announced that results from its PIX301 phase 3 clinical trial of Pixuvri (pixantrone) have been published online in The Lancet Oncology.

31 May 2012

Pfizer’s XALKORI now available in Canada

Pfizer Canada is pleased to announce that XALKORI (crizotinib) is now available in Canada. Recently approved with conditions by Health Canada, XALKORI is an oral monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).

31 May 2012

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

Physicians and researchers at John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 cancer centers, will present the latest findings in blood-cancer research at the 2012 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1-5. Their involvement in these studies is part of John Theurer Cancer Center's continued focus to bolster its research program.

30 May 2012

Sequenom MassARRAY System detects EML4/ALK fusion gene in NSCLC

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today reported on a recently released publication in which the Sequenom MassARRAY System (for research use only) was used in a groundbreaking independent study that detected the transforming fusion gene EML4/ALK in non-small cell lung cancer.

30 May 2012

Scientists develop synthetic peptide that overcomes cancer cells’ survival defenses

Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

30 May 2012

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Cytune Pharma, an emerging leader in innovative immunomodulatory agents against cancer and infectious diseases, announced today that it will attend the BIO2012 to present its major achievements over the last 12 months and to foster partnering discussions.

30 May 2012

Safety of breast implants

Following the recent scandal, described in May 2012 by the BBC as the “PIP breast implant scandal”, (1) many women may have been put off having breast implants. But how safe exactly is breast enlargement? And how do the different methods compare?

29 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patient's own immune response against glioma stem cells.

28 May 2012

Molecular Therapy releases characteristics and activity of SNS01 formulation

Senesco Technologies, Inc., announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.

24 May 2012

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Seattle Genetics, Inc. announced today that the validation period is complete and Health Canada has accepted for review its New Drug Submission (NDS) for the use of ADCETRIS (brentuximab vedotin) in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma.

24 May 2012

Scientists may be step closer to developing new therapy for AML

Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill leukemia cells much more effectively when combined than when the drugs are administered individually.

23 May 2012

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012